Similar articles for PMID: 21511293

Year	Number of Results
2000	3
2002	1
2003	1
2004	2
2005	2
2006	9
2007	3
2008	2
2009	3
2010	7
2011	15
2012	19
2013	9
2014	6
2015	5
2016	4
2017	9
2018	3
2019	3
2020	5
2021	3
2022	4
2024	0

1

Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.

Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M. Kosaka T, et al. J Urol. 2011 Jun;185(6):2376-81. doi: 10.1016/j.juro.2011.02.016. Epub 2011 Apr 20. J Urol. 2011. PMID: 21511293

2

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M. Yasumizu Y, et al. J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15. J Urol. 2014. PMID: 23954373

3

Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.

Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Oya M. Kosaka T, et al. Prostate. 2011 Oct 1;71(14):1510-7. doi: 10.1002/pros.21367. Epub 2011 Feb 14. Prostate. 2011. PMID: 21321983

4

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Kijima T, et al. BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348

5

Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.

Yoo J, Park SS, Lee YJ. Yoo J, et al. J Cell Biochem. 2008 Aug 1;104(5):1636-46. doi: 10.1002/jcb.21729. J Cell Biochem. 2008. PMID: 18404675

6

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.

Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A. Tang Y, et al. Clin Cancer Res. 2006 Jan 1;12(1):169-74. doi: 10.1158/1078-0432.CCR-05-1388. Clin Cancer Res. 2006. PMID: 16397039

7

Survivin mediates resistance to antiandrogen therapy in prostate cancer.

Zhang M, Latham DE, Delaney MA, Chakravarti A. Zhang M, et al. Oncogene. 2005 Apr 7;24(15):2474-82. doi: 10.1038/sj.onc.1208490. Oncogene. 2005. PMID: 15735703

8

PC-1/PrLZ contributes to malignant progression in prostate cancer.

Zhang H, Wang J, Pang B, Liang RX, Li S, Huang PT, Wang R, Chung LW, Zhau HE, Huang C, Zhou JG. Zhang H, et al. Cancer Res. 2007 Sep 15;67(18):8906-13. doi: 10.1158/0008-5472.CAN-06-4214. Cancer Res. 2007. PMID: 17875733

9

High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.

Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. Fizazi K, et al. Anticancer Res. 2004 Sep-Oct;24(5A):2897-903. Anticancer Res. 2004. PMID: 15517894 Free article.

10

Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.

Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K, Suzuki K. Morikawa Y, et al. Biochem Biophys Res Commun. 2012 Mar 16;419(3):584-9. doi: 10.1016/j.bbrc.2012.02.089. Epub 2012 Feb 24. Biochem Biophys Res Commun. 2012. PMID: 22387542

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year